Destenotil – a combination of Troxerutin and Aescin to treat inner ear perfusion disturbances

Destenotil is a fixed combination of troxerutin (450mg) and aescin (25mg) per capsule. Indications for this combination are inner ear perfusion problems of different aetiology. The efficacy of Destenotil (n=34) versus pentoxyfyllin (n=34 patients) was tested in a randomized clinical study as group comparison; end point was the improvement of hearing after 40–44 days of treatment. Hearing was measured by threshold audiometry; a difference of >10dB was judged as a significant improvement.

Results: After Destenotil treatment hearing was significantly improved, in 23 of 34 patients the threshold was changed more than 10dB (sign-test, p<0.05). With pentoxyfyllin hearing was also improved, albeit to a lesser degree. Both drugs were well tolerated, major adverse drug effects were not observed with either treatment.